Literature DB >> 17049380

Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model.

Justin G Julander1, John D Morrey, Lawrence M Blatt, Kristiina Shafer, Robert W Sidwell.   

Abstract

Antiviral compounds were evaluated for efficacy against yellow fever virus (YFV) in a hamster model of YFV-induced liver disease. Challenge with a 10(2) 50% cell culture infectious doses of YFV resulted in a 50-80% mortality rate in female hamsters. Virus was detected by quantitative real-time RT-PCR (QRT-PCR) in liver, kidney, spleen and serum with peak titers on 4-6 days post-viral challenge (dpi). Serum levels of alkaline phosphatase, alanine aminotransferase (ALT), bilirubin, blood urea nitrogen, potassium and creatinine were significantly elevated, while serum levels of albumin, amylase, glucose, calcium, globulin, phosphorus, sodium and total protein were significantly reduced. Packed cell volume and white blood cell count were significantly elevated during the course of the infection. Intraperitoneal treatment of hamsters with 0.5-5 microg/kg/day interferon (IFN) alfacon-1, 100mg/kg/day viramidine or 50 mg/kg/day ribavirin, initiated 4h prior to YFV challenge, resulted in significant improvement in survival and serum ALT levels. Treatment with IFN alfacon-1 or ribavirin starting 2dpi, also significantly improved survival and serum ALT levels in hamsters challenged with YFV. Pre- and post-virus exposure treatment with IFN alfacon-1 was efficacious in improving disease in YFV-infected hamsters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17049380      PMCID: PMC1828627          DOI: 10.1016/j.antiviral.2006.08.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  31 in total

1.  Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.

Authors:  Maria H Sjogren; Robert Sjogren; Kent Holtzmuller; Bradley Winston; Betty Butterfield; Stanley Drake; Amber Watts; Robin Howard; Milton Smith
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

2.  Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart.

Authors:  T De Brito; S A Siqueira; R T Santos; E S Nassar; T L Coimbra; V A Alves
Journal:  Pathol Res Pract       Date:  1992-02       Impact factor: 3.250

3.  Imported yellow fever in a United States citizen.

Authors:  J M McFarland; L M Baddour; J E Nelson; S K Elkins; R B Craven; B C Cropp; G J Chang; A D Grindstaff; A S Craig; R J Smith
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

4.  In vitro and in vivo influenza virus-inhibitory effects of viramidine.

Authors:  Robert W Sidwell; K W Bailey; M-H Wong; D L Barnard; D F Smee
Journal:  Antiviral Res       Date:  2005-10       Impact factor: 5.970

5.  Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values.

Authors:  Elena Sbrana; Shu-Yuan Xiao; Vsevolod L Popov; Patrick C Newman; Robert B Tesh
Journal:  Am J Trop Med Hyg       Date:  2006-06       Impact factor: 2.345

6.  Long-term effect of hepatitis C virus chronic infection on patient and renal graft survival.

Authors:  O Bestard; J M Cruzado; J Torras; S Gil-Vernet; D Serón; F Moreso; I Rama; J M Grinyó
Journal:  Transplant Proc       Date:  2005-11       Impact factor: 1.066

7.  Interferon alfacon-1 protects hamsters from lethal pichinde virus infection.

Authors:  Brian B Gowen; Dale L Barnard; Donald F Smee; Min-Hui Wong; Anne M Pace; Kie-Hoon Jung; Scott G Winslow; Kevin W Bailey; Lawrence M Blatt; Robert W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium.

Authors:  Hi-Gung Bae; Christian Drosten; Petra Emmerich; Robert Colebunders; Philippe Hantson; Stefan Pest; Muriel Parent; Herbert Schmitz; Marc-Aurel Warnat; Matthias Niedrig
Journal:  J Clin Virol       Date:  2005-01-15       Impact factor: 3.168

9.  Comparison of the in vitro host range of recombinant met-interferon-con1, interferon-alpha 2b, and interferon-beta [corrected].

Authors:  C J Hu; O N Ozes; S B Klein; L M Blatt; M W Taylor
Journal:  J Interferon Cytokine Res       Date:  1995-03       Impact factor: 2.607

10.  Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

Authors:  Erin Mehlhop; Michael S Diamond
Journal:  J Exp Med       Date:  2006-05-01       Impact factor: 14.307

View more
  24 in total

1.  Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential.

Authors:  Michael Zasloff; A Paige Adams; Bernard Beckerman; Ann Campbell; Ziying Han; Erik Luijten; Isaura Meza; Justin Julander; Abhijit Mishra; Wei Qu; John M Taylor; Scott C Weaver; Gerard C L Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.

Authors:  Justin G Julander; Shanta Bantia; Brian R Taubenheim; Dena M Minning; Pravin Kotian; John D Morrey; Donald F Smee; William P Sheridan; Yarlagadda S Babu
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

4.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

Review 5.  Experimental therapies for yellow fever.

Authors:  Justin G Julander
Journal:  Antiviral Res       Date:  2012-12-10       Impact factor: 5.970

6.  Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.

Authors:  Justin G Julander; Brett A Thibodeaux; John D Morrey; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2014-01-03       Impact factor: 5.970

7.  Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.

Authors:  Justin G Julander; Kristiina Shafer; Donald F Smee; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever.

Authors:  Brian B Gowen; Justin G Julander; Nyall R London; Min-Hui Wong; Deanna Larson; John D Morrey; Dean Y Li; Mike Bray
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

9.  Docking Studies of Adenosine Analogues with NS5 Methyltransferase of Yellow Fever Virus.

Authors:  Kh Dhanachandra Singh; Palani Kirubakaran; S Manikandaprabhu; S Nagamani; P Srinivasan; M Karthikeyan
Journal:  Indian J Microbiol       Date:  2011-08-09       Impact factor: 2.461

10.  A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein.

Authors:  Fang Guo; Shuo Wu; Justin Julander; Julia Ma; Xuexiang Zhang; John Kulp; Andrea Cuconati; Timothy M Block; Yanming Du; Ju-Tao Guo; Jinhong Chang
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.